BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 31839432)

  • 41. Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas.
    Bohlen M; Busch C-; Sehner S; Forterre F; Bier J; Berliner C; Bußmann L; Münscher A
    Eur Arch Otorhinolaryngol; 2019 Apr; 276(4):1183-1189. PubMed ID: 30725209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stathmin guides personalized therapy in oral squamous cell carcinoma.
    Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
    Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer.
    Noronha V; Patil V; Chaturvedi P; Mathrudev V; Menon N; Bhattacharjee A; Singh A; Peelay Z; Chakraborty S; Jadhav M; Alone M; Bhagyavant P; Kolkur M; Srinivas S; Das S; Roy S; Mandal T; Dsouza H; Saha S; Rai R; Srikanth A; Shah D; Khan A; Muthuluri H; Kumar A; Agarwal A; Rajpurohit A; Goli VB; Sekar A; Mantri A; Kanteti APK; Majumdar S; Khaddar S; Shenoy R; Elamarthi P; Rathnasamy N; Kashyap L; Abraham G; Booma N; Simha V; Chaukar D; Pai P; Nair S; Laskar S; Nawale K; Naidu P; Salian S; Shelar P; Raulo R; Dhumal SB; Prabhash K
    Eur J Cancer; 2024 Mar; 200():113560. PubMed ID: 38306841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M
    Clin Oncol (R Coll Radiol); 2005 May; 17(3):148-52. PubMed ID: 15900997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
    Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J
    Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
    Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N
    Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
    Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI;
    Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Yuan TZ; Zheng RH
    J Cancer; 2021; 12(1):18-27. PubMed ID: 33391399
    [No Abstract]   [Full Text] [Related]  

  • 52. Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
    Szturz P; Vinches M; Remenár É; van Herpen CML; Abdeddaim C; Stewart JS; Fortpied C; Vermorken JB
    Eur J Cancer; 2021 Oct; 156():109-118. PubMed ID: 34425403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area.
    Xu C; Yang SP; Zhang Y; Tang LL; Zhou GQ; Liu X; Mao YP; Guo R; Li WF; Chen L; Lin AH; Sun Y; Ma J
    Cancer Res Treat; 2018 Jul; 50(3):777-790. PubMed ID: 28745036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
    Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
    Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of TPF and TP Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma Based on TNM Stage and Pretreatment Systemic Immune-Inflammation Index.
    Xiong Y; Shi L; Zhu L; Peng G
    Front Oncol; 2021; 11():731543. PubMed ID: 34616680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02).
    Frikha M; Auperin A; Tao Y; Elloumi F; Toumi N; Blanchard P; Lang P; Sun S; Racadot S; Thariat J; Alfonsi M; Tuchais C; Cornely A; Moussa A; Guigay J; Daoud J; Bourhis J;
    Ann Oncol; 2018 Mar; 29(3):731-736. PubMed ID: 29236943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
    Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
    Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
    N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study.
    Chang PM; Lu HJ; Wang LW; Tai SK; Chen MH; Chu PY; Yang MH
    Head Neck; 2017 Jul; 39(7):1333-1342. PubMed ID: 28370774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.